Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04498741 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT04498741 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT04498741, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of tacrolimus, dabigatran, rosuvastatin and midazolam on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Interventions
- DRUG Tacrolimus
- DRUG Dabigatran
- DRUG EDP-938
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2020-07-08 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04498741
The ClinicalTrials.gov registry entry for NCT04498741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT04498741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04498741 about?
NCT04498741 is a clinical study titled "Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects". A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of tacrolimus, dabigatran, rosuvastatin and midazolam on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
What is the current status of trial NCT04498741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2020-07-08. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT04498741?
The interventions under investigation include: Tacrolimus (DRUG), Dabigatran (DRUG), EDP-938 (DRUG).
Who is sponsoring clinical trial NCT04498741?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.